Finance

Lists
Outlook: 34.5% bullish·20.7% bearish
Go to analysis
BNTX:NASDAQ
BioNTech SE - ADR
$89.21
+1.71%
(+1.50) 1D
$89.21
0.00% (0.00)
After hours
Closed: Oct 19, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BNTX...
Open
$88.10
High
$89.80
Low
$87.72
Mkt. cap
22.41B
Avg. vol.
965.98K
Volume
1.34M
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.54
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
Open
$88.10
High
$89.80
Low
$87.72
Mkt. cap
22.41B
Avg. vol.
965.98K
Volume
1.34M
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.54
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases. The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes. In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR
CEO-
Employees7.81K
Founded2008
Headquarters-
SectorBiotechnology
Websitebiontech.de
Analyst ratings
Based on 15 analysts giving stock ratings to BNTX in the past 3 months
Buy
Buy
11
Hold
4
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for BNTX in the last 3 months.
Highest
Current $89.21
$140.00 (+56.93%)
Average
$125.85 (+41.07%)
Lowest
$96.00 (+7.61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Terence Flynn
Morgan Stanley
Buy
Reiterated
$114.00
+27.8%
10/19/2026
John Newman
Canaccord Genuity
Buy
Maintained
$132.00
+48%
10/19/2026
Asad Haider
Goldman Sachs
Buy
Maintained
$127.00
+42.4%
10/13/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$130.00
+45.7%
10/13/2026
Geoff Meacham
Citi
Buy
Maintained
$125.00
+40.1%
10/13/2026
Evan Seigerman
BMO Capital
Hold
Maintained
$105.00
+17.7%
10/12/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$114.00
+27.8%
10/09/2026
John Eade
Argus Research
Hold
Initiated
-
-
10/07/2026
Harry Gillis
Berenberg Bank
Buy
Maintained
$140.00
+56.9%
10/07/2026
Luisa Hector
Berenberg Bank
Buy
Maintained
$140.00
+56.9%
10/07/2026
Jeffrey Walch
Bernstein
Hold
Maintained
$96.00
+7.6%
09/25/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
$140.00
+56.9%
09/24/2026
David Dai
UBS
Buy
Maintained
$135.00
+51.3%
09/16/2026
Akash Tewari
Jefferies
Buy
Maintained
$138.00
+54.7%
09/15/2026
Emmanuel Papadakis
Deutsche Bank
Buy
Maintained
$140.00
+56.9%
08/26/2026
Jessica Fye
J.P. Morgan
Hold
Maintained
-
-
08/19/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$140.00
+56.9%
08/05/2026
Unknown Analyst
Bernstein
Hold
Maintained
-
-
06/01/2026
Unknown Analyst
J.P. Morgan
Hold
Maintained
$100.00
+12.1%
05/20/2026
Yaron Werber
TD Cowen
Hold
Maintained
$94.00
+5.4%
05/05/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$130.00
+45.7%
04/27/2026
Asthika Goonewardene
Truist Financial
Buy
Maintained
$155.00
+73.7%
03/13/2026
William Maughan
Clear Street
Buy
Reiterated
$167.00
+87.2%
03/11/2026
Daina Graybosch
Leerink Partners
Hold
Downgraded
$113.00
+26.7%
02/02/2026
Last report
Aug 4, 2026
Fiscal period
Q2 2026
-€2.22 / -€2.08
-6.80%miss
Revenue / Est. (EUR)
105.60M / 155.71M
-32.18%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.52B
907.40M
118.10M
105.60M
Cost of goods sold
148.30M
302.80M
71.40M
97.00M
Cost of revenue
148.30M
302.80M
71.40M
97.00M
Research and development expenses
564.80M
505.40M
557.00M
477.10M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
148.50M
217.90M
150.80M
197.80M
Operating expense
1.40B
907.20M
727.70M
860.40M
Total operating expenses
1.55B
1.21B
799.10M
957.40M
Operating income
-33.00M
-302.60M
-681.00M
-851.80M
Other non operating income
96.80M
-173.80M
42.10M
23.80M
EBT including unusual items
24.70M
-227.40M
-568.10M
-858.70M
EBT excluding unusual items
40.70M
-206.50M
-567.80M
-777.70M
Income tax expense
53.40M
77.60M
-36.20M
-37.90M
Effective tax rate
216.19%
-34.12%
6.37%
4.41%
Other operating expenses
690.30M
183.90M
19.90M
185.50M
Net income
-28.70M
-305.00M
-531.90M
-820.80M
Net profit margin
-1.89%
-33.61%
-450.38%
-777.27%
Earnings per share
-0.12
-0.33
-1.95
-2.22
Interest and investment income
-
265.50M
61.70M
66.40M
Interest expense
-2.60M
-
-4.00M
-3.50M
Net interest expenses
-2.60M
265.50M
57.70M
62.90M
Depreciation and amortization charges
-
-
-
-
EBITDA
91.20M
-266.95M
-559.70M
-585.70M
Gain or loss from assets sale
-1.30M
-800.00K
-100.00K
-900.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps